Drug intelligence / Profile preview

AGEX-BAT1

Development stage: Discontinued
Lead developer: Serina Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Implant

Overview

AGEX-BAT1 is a preclinical cell-based therapy consisting of pluripotent stem cell-derived brown adipose tissue (BAT) cells. Developed by AgeX Therapeutics (a subsidiary of BioTime, which merged with Serina Therapeutics in 2023), the candidate is intended to treat metabolic disorders including Type 2 diabetes and obesity. Brown fat is specialized for thermogenesis, and the transplantation of these cells aims to increase energy expenditure, improve glucose metabolism, and enhance insulin sensitivity. Preclinical studies in murine models, conducted in collaboration with Ohio State University, have also explored its potential to improve cardiac function and address cardiovascular disease.

Other names: brown fat cells

Beyond the preview

Go deeper on AGEX-BAT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGEX-BAT1.

Explore the full profile